These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 3471321

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH, de Graaf SS, Dow LW, Rodman JH, Evans WE, Alpert BS, Murphy SB.
    Cancer Res; 1988 Sep 15; 48(18):5348-52. PubMed ID: 3165708
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
    Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM.
    Cancer Res; 1990 Oct 15; 50(20):6525-8. PubMed ID: 2208112
    [Abstract] [Full Text] [Related]

  • 5. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
    Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L.
    Cancer Res; 1985 Mar 15; 45(3):1408-12. PubMed ID: 3855696
    [Abstract] [Full Text] [Related]

  • 6. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 15; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT, Hancock CH, Mondora A, Hoffman NW.
    Cancer Res; 1984 Feb 15; 44(2):831-5. PubMed ID: 6692381
    [Abstract] [Full Text] [Related]

  • 8. Clinical studies with rubidazone.
    Benjamin RS, Keating MJ, Swenerton KD, Legha S, McCredie KB.
    Cancer Treat Rep; 1979 May 15; 63(5):925-9. PubMed ID: 287557
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
    O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M.
    Cancer Res; 1991 Feb 01; 51(3):935-8. PubMed ID: 1988134
    [Abstract] [Full Text] [Related]

  • 10. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, de Witte T.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [Abstract] [Full Text] [Related]

  • 11. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
    Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW.
    Cancer Res; 1983 Dec 01; 43(12 Pt 1):6096-101. PubMed ID: 6580068
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L, Dalmark M.
    Cancer Treat Rep; 1987 May 01; 71(5):451-4. PubMed ID: 3471329
    [Abstract] [Full Text] [Related]

  • 13. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
    Berman E, Raymond V, Daghestani A, Arlin ZA, Gee TS, Kempin S, Hancock C, Williams L, Stevens YW, Clarkson BD.
    Cancer Res; 1989 Jan 15; 49(2):477-81. PubMed ID: 2910465
    [Abstract] [Full Text] [Related]

  • 14. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
    Fujita H, Ogawa M, Masaoka T, Yamada K, Kimura K.
    Gan To Kagaku Ryoho; 1992 Jun 15; 19(6):791-8. PubMed ID: 1605655
    [Abstract] [Full Text] [Related]

  • 15. [A phase I trial of idarubicin by oral administration].
    Ogawa M, Kimura K, Taguchi T, Wakui A, Hattori M, Shimoyama T, Fujita H.
    Gan To Kagaku Ryoho; 1987 Jun 15; 14(6 Pt 1):1896-900. PubMed ID: 3473981
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 17. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M, Masaoka T, Yamada K, Kimura K.
    Gan To Kagaku Ryoho; 1993 May 15; 20(7):897-906. PubMed ID: 8489296
    [Abstract] [Full Text] [Related]

  • 18. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 May 15; 82(5 Suppl):19-22. PubMed ID: 9402749
    [Abstract] [Full Text] [Related]

  • 19. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 May 15; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
    Madon E, Grazia G, De Bernardi B, Comelli A, Carli M, Sainati L, Paolucci G, Canino R, Colella R, Bagnulo S.
    Cancer Treat Rep; 1987 Sep 15; 71(9):855-6. PubMed ID: 3476202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.